Related references
Note: Only part of the references are listed.Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Eytan M. Stein et al.
BLOOD (2021)
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Bin Fan et al.
INVESTIGATIONAL NEW DRUGS (2020)
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation
Bin Fan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans
Zeen Tong et al.
XENOBIOTICA (2019)
Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects
Chandra Prakash et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects
David Dai et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
Yan Li et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine Yen et al.
CANCER DISCOVERY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
IDH mutations in cancer and progress toward development of targeted therapeutics
L. Dang et al.
ANNALS OF ONCOLOGY (2016)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Daniel J. Brat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
